British Journal of Cancer - Table of Contents alert Volume 111 Issue 11

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 111, Issue 11 (2033-2204) Published online 25 November 2014 In this issue Minireviews Clinical Studies Translational Therapeutics Molecular Diagnostics Epidemiology Letters to the Editor Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Don't miss out! Discover which British Journal of Cancer articles your colleagues are reading? Top Ten Articles.   Minireviews Top Targeting molecular addictions in cancer I Vivanco Br J Cancer 2014 111: 2033-2038; advance online publication, September 30, 2014; 10.1038/bjc.2014.461 Abstract | Full Text Unlocking the potential of retinoic acid in anticancer therapy T Schenk, S Stengel and A Zelent Br J Cancer 2014 111: 2039-2045; advance online publication, November 20, 2014; 10.1038/bjc.2014.412 Abstract | Full Text Clinical Studies Top Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy Y Chavarri-Guerra, M J Higgins, J Szymonifka, T Cigler, P Liedke, A Partridge, J Ligibel, S E Come, D Finkelstein, P D Ryan and P E Goss Br J Cancer 2014 111: 2046-2050; advance online publication, September 18, 2014; 10.1038/bjc.2014.502 Abstract | Full Text Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses T Brodowicz, I Lang, Z Kahan, R Greil, S Beslija, S M Stemmer, B Kaufman, L Petruzelka, A Eniu, R Anghel, K Koynov, D Vrbanec, T Pienkowski, B Melichar, S Spanik, S Ahlers, D Messinger, M J Inbar and C Zielinski Br J Cancer 2014 111: 2051-2057; advance online publication, September 30, 2014; 10.1038/bjc.2014.504 Abstract | Full Text Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study S J Isakoff, D Wang, M Campone, A Calles, E Leip, K Turnbull, N Bardy-Bouxin, L Duvillié and E Calvo Br J Cancer 2014 111: 2058-2066; advance online publication, October 7, 2014; 10.1038/bjc.2014.508 Abstract | Full Text Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study E Van Cutsem, C-P Li, E Nowara, G Aprile, M Moore, I Federowicz, J-L Van Laethem, C Hsu, C K Tham, S M Stemmer, R Lipp, A Zeaiter, A Fittipaldo, Z Csutor, B Klughammer, X Meng and T Ciuleanu Br J Cancer 2014 111: 2067-2075; advance online publication, September 23, 2014; 10.1038/bjc.2014.494 Abstract | Full Text Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers M D Gill, M G Bramble, M A Hull, S J Mills, E Morris, D M Bradburn, Y Bury, C E Parker, T J W Lee and C J Rees Br J Cancer 2014 111: 2076-2081; advance online publication, September 23, 2014; 10.1038/bjc.2014.498 Abstract | Full Text Prognostic impact of histological categorisation of epithelial–mesenchymal transition in colorectal cancer H Ueno, E Shinto, Y Kajiwara, S Fukazawa, H Shimazaki, J Yamamoto and K Hase Br J Cancer 2014 111: 2082-2090; advance online publication, September 23, 2014; 10.1038/bjc.2014.509 Abstract | Full Text Translational Therapeutics Top microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome P Akçakaya, S Caramuta, J Åhlen, M Ghaderi, E Berglund, A Östman, R Bränström, C Larsson and W-O Lui Br J Cancer 2014 111: 2091-2102; advance online publication, October 30, 2014; 10.1038/bjc.2014.548 Abstract | Full Text Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy A Sathe, F Guerth, M V Cronauer, M M Heck, M Thalgott, J E Gschwend, M Retz and R Nawroth Br J Cancer 2014 111: 2103-2113; advance online publication, November 4, 2014; 10.1038/bjc.2014.534 Abstract | Full Text Molecular Diagnostics Top SERPINE1 and SMA expression at the invasive front predict extracapsular spread and survival in oral squamous cell carcinoma J Dhanda, A Triantafyllou, T Liloglou, H Kalirai, B Lloyd, R Hanlon, R J Shaw, D R Sibson and J M Risk Br J Cancer 2014 111: 2114-2121; advance online publication, September 30, 2014; 10.1038/bjc.2014.500 Abstract | Full Text SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma S H Lee, S-Y Oh, S I Do, H J Lee, H J Kang, Y S Rho, W J Bae and Y C Lim Br J Cancer 2014 111: 2122-2130; advance online publication, October 16, 2014; 10.1038/bjc.2014.528 Abstract | Full Text A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma Y-W Sun, Y-F Chen, J Li, Y-M Huo, D-J Liu, R Hua, J-F Zhang, W Liu, J-Y Yang, X-L Fu, T Yan, J Hong and H Cao Br J Cancer 2014 111: 2131-2141; advance online publication, October 14, 2014; 10.1038/bjc.2014.520 Abstract | Full Text Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo S Winsel, J Mäki-Jouppila, M Tambe, M R Aure, S Pruikkonen, A-L Salmela, T Halonen, S-K Leivonen, L Kallio, A-L Børresen-Dale and M J Kallio Br J Cancer 2014 111: 2142-2151; advance online publication, September 30, 2014; 10.1038/bjc.2014.524 Abstract | Full Text Epidemiology Top Predictors of adherence to repeat fecal occult blood test in a population-based colorectal cancer screening program C Pornet, B Denis, P Perrin, I Gendre and G Launoy Br J Cancer 2014 111: 2152-2155; advance online publication, October 14, 2014; 10.1038/bjc.2014.507 Abstract | Full Text Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm J Geraghty, P Butler, H Seaman, J Snowball, S Sarkar, R Blanks, S Halloran, K Bodger and C J Rees Br J Cancer 2014 111: 2156-2162; advance online publication, September 16, 2014; 10.1038/bjc.2014.480 Abstract | Full Text Association of serum α-tocopherol, β-carotene, and retinol with liver cancer incidence and chronic liver disease mortality G Y Lai, S J Weinstein, D Albanes, P R Taylor, J Virtamo, K A McGlynn and N D Freedman Br J Cancer 2014 111: 2163-2171; advance online publication, October 14, 2014; 10.1038/bjc.2014.365 Abstract | Full Text Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies X-F Ye, J Wang, W-T Shi and J He Br J Cancer 2014 111: 2172-2179; advance online publication, September 2, 2014; 10.1038/bjc.2014.481 Abstract | Full Text Independent and joint effect of type 2 diabetes and gastric and hepatobiliary diseases on risk of pancreatic cancer risk: 10-year follow-up of population-based cohort C-C Lin, J-H Chiang, C-I Li, T-F Hsieh, C-S Liu, W-Y Lin, Y-D Lee and T-C Li Br J Cancer 2014 111: 2180-2186; advance online publication, October 2, 2014; 10.1038/bjc.2014.525 Abstract | Full Text Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial K Haguenoer, S Sengchanh, C Gaudy-Graffin, J Boyard, R Fontenay, H Marret, A Goudeau, N Pigneaux de Laroche, E Rusch and B Giraudeau Br J Cancer 2014 111: 2187-2196; advance online publication, September 23, 2014; 10.1038/bjc.2014.510 Abstract | Full Text Letters to the Editor Top Comment on ‘The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005)’: the effect of left censoring A Farioli, S Mattioli, S Curti and F S Violante Br J Cancer 2014 111: 2197-2198; advance online publication, August 5, 2014; 10.1038/bjc.2014.440 Full Text Response to comment on ‘The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005)’ G Frost Br J Cancer 2014 111: 2198-2199; advance online publication, August 5, 2014; 10.1038/bjc.2014.441 Full Text Comment on ‘Residential distance at birth from overhead high-voltage powerlines: childhood cancer risk in Britain 1962–2008’ D Jeffers Br J Cancer 2014 111: 2199-2200; advance online publication, November 11, 2014; 10.1038/bjc.2014.334 Full Text Comment on ‘The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis’ M A Malik Br J Cancer 2014 111: 2200; advance online publication, April 15, 2014; 10.1038/bjc.2014.184 Full Text Reply: Comment on ‘The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis’ B Lajin and A Alachkar Br J Cancer 2014 111: 2201; advance online publication, April 15, 2014; 10.1038/bjc.2014.186 Full Text Need for clarification of data in a recent meta-analysis on the association of NQO1 C609T polymorphism with cancer risk X Cao and W Shen Br J Cancer 2014 111: 2201-2202; advance online publication, October 28, 2014; 10.1038/bjc.2014.212 Full Text Reply to ‘Comment on: The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis’ B Lajin and A Alachkar Br J Cancer 2014 111: 2202; advance online publication, October 28, 2014; 10.1038/bjc.2014.295 Full Text Distinguishing sedentary from inactive: implications for meta-analyses B M Lynch and T Boyle Br J Cancer 2014 111: 2202-2203; advance online publication, February 25, 2014; 10.1038/bjc.2014.106 Full Text Reply: Comment on ‘Association of sedentary behaviour with colon and rectal cancer: a meta-analysis of observational studies’ Z Lu, S Cao, Y Gan and Y Cong Br J Cancer 2014 111: 2203; advance online publication, February 25, 2014; 10.1038/bjc.2014.107 Full Text Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer A Choughule, R Sharma, V Trivedi, A Thavamani, V Noronha, A Joshi, S Desai, P Chandrani, P Sundaram, S Utture, N Jambhekar, S Gupta, J Aich, K Prabhash and A Dutt Br J Cancer 2014 111: 2203-2204; advance online publication, August 12, 2014; 10.1038/bjc.2014.401 Full Text Advertisement British Journal of Cancer has you covered. The British Journal of Cancer publishes significant research that increases the understanding of the causes of cancer; informs about timely detection and accurate diagnosis; helps develop personalised therapy; and drives improvements in the treatment and survival of patients.  Subscribe today and don't miss a beat.   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.